netFormulary NHS
North East and North Cumbria
ICS Formulary
 Search
 Recent Updates - Updated items

All Formulary Amendments

  Records 1 to 15 of 15


Details
UPD sitematrix Changed from 0 to
11/07/2023 17:46:21
(dmcdermott )
UPD FurtherInformation Changed from

  • Approved for use in accordance with NICE and NHS EnglandCommissioning Policy


 

to
  • Approved for use in accordance with NICE and NHS EnglandCommissioning Policy
11/07/2023 17:46:21
(dmcdermott )
UPD Dasatinib (Sprycel®) =
11/07/2023 17:46:21
(dmcdermott )
LDL Link Added : MHRA Drug Safety Update (May 2016): BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation : https://www.gov.uk/drug-safety-update/bcr-abl-tyrosine-kinase-inhibitors-risk-of-hepatitis-b-reactivation
11/07/2023 17:45:59
(dmcdermott )
UPD sitematrix Changed from 0 to
17/12/2021 12:31:23
(LoweryM )
UPD FurtherInformation Changed from
  • Approved for use in accordance with NICE and NHS Commissioning Policy
to
  • Approved for use in accordance with NICE and NHS EnglandCommissioning Policy

 

17/12/2021 12:31:23
(LoweryM )
UPD Dasatinib (Sprycel®) formatting
17/12/2021 12:31:23
(LoweryM )
UPD Dasatinib (Sprycel®) Updated
09/08/2017 16:09:46
(DavidS )
UPD Dasatinib (Sprycel®) B
03/02/2017 14:50:21
(LoweryM )
LDL Link Added : NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia : https://www.nice.org.uk/guidance/ta426/
31/01/2017 16:06:10
(DavidS )
UPD Dasatinib (Sprycel®) b
31/01/2017 16:05:03
(DavidS )
LDL Link Added : NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia : https://www.nice.org.uk/guidance/ta425
31/01/2017 16:03:30
(DavidS )
UPD Dasatinib (Sprycel®) b
31/01/2017 16:03:02
(DavidS )
UPD Dasatinib (Sprycel®) b
23/01/2017 15:37:39
(WhitehallJ )
UPD Dasatinib (Sprycel®) build
28/11/2016 15:40:36
(DavidS )

 

 

netFormulary